Curcumin phospholipid complex, oral preparation and preparation method of curcumin phospholipid complex

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a curcumin-phospholipid complex, an oral preparation and a preparation method of the curcumin-phospholipid complex, the curcumin-phospholipid complex comprises curcumin and marine phospholipid, the molar ratio of the curcumin to the marine phospholipid is (1-5): (1-10), and the curcumin-phospholipid complex is prepared according to the following steps that the curcumin and the marine phospholipid are taken and placed in an organic solvent; the mass concentration of a reactant is 2-20 mg / ml, magnetic stirring is carried out for 1-3 h at the temperature of 30-70 DEG C, rotary evaporation is carried out, diethyl ether is added to remove unreacted curcumin, vacuum drying is carried out for 8-14 h after reduced-pressure rotary evaporation, and the curcumin phospholipid complex is obtained and can increase the water solubility and stability of curcumin, remarkably improve the bioavailability of the curcumin raw material and reduce the dosage.

Description

[0001] This patent claims priority to the following patent: patent application number 202411893344.X, patent application date 2024-12-20, patent title: A curcumin-phospholipid complex and its preparation method. Technical Field

[0002] This invention belongs to the field of pharmaceutical technology, specifically relating to a curcumin phospholipid complex, an oral preparation thereof, and a method for its preparation. Background Technology

[0003] Curcumin is a polyphenol with a relatively small molecular weight extracted from the ginger family plant (Curcuma longa L.), and it has both medicinal and edible value. Studies have found that curcumin has a wide range of pharmacological activities, such as antioxidant, anti-inflammatory, anticancer, antibacterial, hypoglycemic, lipid-lowering, and neuroprotective activities. Clinical results show that curcumin has a high safety profile; even with high-dose oral administration of 12g / day, no toxic reactions were observed in humans. Due to its superior pharmacological activity and safe, non-toxic characteristics, it has attracted increasing attention from pharmaceutical researchers. However, curcumin has drawbacks such as low water solubility, poor stability, rapid metabolism in vivo, and low bioavailability (oral bioavailability is only 1%), which significantly limits its application in the food and pharmaceutical fields.

[0004] Curcumin, when taken in its original form, cannot achieve the desired therapeutic effect, thus new formulation methods are urgently needed to enable it to exert its ideal pharmacological effects. Although liposomes, micelles, and microemulsions are currently available formulations, they still have drawbacks such as low drug loading capacity, rapid metabolism, and low bioavailability, thus requiring further research.

[0005] Phospholipid complexes are a unified entity formed by the active ingredient and phospholipids through weak interactions, distinct from a physical mixture of the two. Under certain conditions, some poorly soluble drug molecules interact with phospholipid molecules through electron gain or loss, forming phospholipid complexes via charge migration. This alters the original physical properties of the drug (such as molecular solubility and in vitro dissolution rate), resulting in greater stability than liposomes. Pharmacokinetic studies have shown that phospholipid complexes can increase the concentration of active molecules in vivo, slow their elimination rate, and thus exhibit higher bioavailability, allowing the active molecules to exert their pharmacological effects more effectively in vivo.

[0006] Currently, phospholipid complexes are all prepared from soybean phospholipids, which mainly contain omega-6 fatty acids (such as linoleic acid). Daily consumption can easily lead to excessive intake. Linoleic acid is primarily metabolized in the liver; excessive intake can increase the burden on the liver and easily cause fatty liver. Furthermore, soybean phospholipids themselves lack bioactive components (such as EPA / DHA in krill phospholipids), and therefore cannot form a synergistic effect with curcumin in anti-inflammatory and antioxidant fields. Additionally, soybeans are a common allergen, and soybean-derived phospholipid complexes may cause adverse reactions in people with soybean allergies. Summary of the Invention

[0007] To address the aforementioned issues, this invention proposes a curcumin phospholipid complex, an oral formulation, and a method for preparing the same. This complex significantly improves the bioavailability of curcumin raw materials and reduces the dosage.

[0008] Phospholipids derived from Antarctic krill are rich in phospholipid-type ω-3 fatty acids and astaxanthin, with EPA and DHA content significantly higher than soybean phospholipids. This not only allows them to synergize with the activity of curcumin but also enhances the permeability of cell membranes and organelle membranes, facilitating phospholipid transport and improving the bioavailability of poorly soluble drugs. They also exhibit superior performance in emulsification and drug delivery. Furthermore, the astaxanthin in krill phospholipids acts as a natural antioxidant, maintaining the stability of the phospholipid complex. This invention, by introducing excipients into the phospholipid complex system to prepare a solid dispersible tablet oral formulation, further improves the physical stability of the complex and enhances its water solubility.

[0009] The first objective of this invention is to provide a novel curcumin phospholipid complex by replacing ordinary low-content krill phospholipids, soybean-derived phospholipids, and Antarctic krill oil with high-purity krill phospholipids, thereby increasing the water solubility and stability of curcumin and improving its bioavailability. The second objective of this invention is to provide a method for preparing the curcumin phospholipid complex. The third objective of this invention is to provide physicochemical characterization results of the water solubility and stability of the curcumin phospholipid complex, as well as an evaluation of its bioavailability.

[0010] The technical solution of the present invention is as follows: A curcumin phospholipid complex in this application comprises curcumin and marine phospholipids, wherein the molar ratio of curcumin to marine phospholipids is (1-5):(1-10).

[0011] Preferably, the molar ratio of curcumin to marine phospholipids is 1:(2-6).

[0012] Preferably, the marine phospholipid is krill phospholipid, and the phospholipid content in the krill phospholipid is not less than 50 wt%.

[0013] Preferably, the phosphatidylcholine content in the krill phospholipids is higher than 50 wt%.

[0014] Preferably, the phosphatidylcholine content in the krill phospholipids is higher than 70 wt%.

[0015] Preferably, the phosphatidylcholine content in the krill phospholipids is higher than 80 wt%.

[0016] Preferably, the phosphatidylcholine content in the krill phospholipids is higher than 95 wt%.

[0017] This application provides a method for preparing a curcumin phospholipid complex, which is carried out according to the following steps: Curcumin and krill phospholipids were placed in an organic solvent at a mass concentration of 2-20 mg / ml. After magnetic stirring at 30-70℃ for 1-3 h, the mixture was rotary evaporated. Unreacted curcumin was removed by adding diethyl ether, and the solvent was removed by rotary evaporation under reduced pressure. The mixture was then vacuum dried for 8-14 h to obtain the curcumin phospholipid complex.

[0018] Preferably, the organic solvent is one or more of tetrahydrofuran, ethyl acetate, and anhydrous ethanol.

[0019] Anhydrous ethanol is preferred. Preferably, the reaction temperature is 50°C. Preferably, the mass concentration of the reactant is 10 mg / ml, and the reaction time is 3 h.

[0020] This application provides an oral formulation of curcumin phospholipid complex, including common oral formulations such as tablets, capsules, granules, powders, and pills.

[0021] Preferably, this application provides a method for preparing tablets: the curcumin phospholipid complex of this application is mixed evenly with an appropriate amount of lubricant, excipient and disintegrant and then compressed into tablets to obtain oral tablets.

[0022] By weight, the tablets comprise: 55-75 parts curcumin phospholipid complex, 0.5-3 parts lubricant, 0.5-5 parts disintegrant, and 20-45 parts excipients.

[0023] Preferably, the lubricant is one or more of magnesium stearate, talc, and silicon dioxide.

[0024] Preferably, the disintegrant is one or more of croscarmellose sodium, croscarmellose sodium, and croscarmellose polyvinylpyrrolidone.

[0025] Preferably, the excipient is one or more of microcrystalline cellulose, dicalcium phosphate, and lactose.

[0026] This invention uses high-purity phospholipids to replace ordinary low-content phospholipids, soybean-derived phospholipids, and Antarctic krill oil to prepare curcumin phospholipid complexes, thereby improving the water solubility and bioavailability of curcumin technical. Attached Figure Description

[0027] The accompanying drawings, which are included to provide a further understanding of this application and form part of this application, illustrate exemplary embodiments and are used to explain this application, but do not constitute an undue limitation of this application. In the drawings: Figure 1 The images show infrared spectra, where a. curcumin; b. krill phospholipids; c. Comparative Example 4 sample; d. Example 1 sample; Figure 2 The images show X-ray diffraction patterns, where a. curcumin; b. krill phospholipids; c. Comparative Example 4 sample; d. Example 1 sample; Figure 3 The image shows the results of the in vitro dissolution experiment. Detailed Implementation

[0028] The following embodiments are provided to further illustrate the present invention. Obviously, the described embodiments are only some, not all, of the embodiments described in this application. All other embodiments obtained by those skilled in the art based on the embodiments described in this application without inventive effort are within the scope of protection claimed in this application.

[0029] Unless otherwise specified, the reagents and instruments used in the following examples are all commercially available products.

[0030] The marine phospholipids used in the examples are phospholipids extracted from Antarctic krill. Commercially available products can be used, or they can be prepared in-house or using existing technologies. Products that meet the requirements of having a phospholipid content of not less than 50 wt% and a phosphatidylcholine content of not less than 50 wt% can be used in this application.

[0031] This application lists several commonly used technical methods: 1. Organic solvent extraction (using acetone or ethanol to remove neutral lipids and free fatty acids from krill; using polar solvents to extract phospholipids from the defatted residue, evaporating the solvent, and then increasing the PC content through column chromatography or low-temperature crystallization). 2. Supercritical fluid extraction (utilizing the solubility of supercritical CO2 to selectively extract lipids; combining with an entrainer (ethanol) can improve the phospholipid recovery rate). 3. Column chromatography purification (using silica gel, alumina, or reversed-phase chromatography columns to separate PC).

[0032] The curcumin phospholipid complexes in the following examples were all prepared according to the following preparation method, and the key parameters involved are detailed in the table below: Preparation method of curcumin phospholipid complex: Curcumin and krill phospholipids are placed in an organic solvent, magnetically stirred and then rotary evaporated. Unreacted curcumin is removed by adding diethyl ether, and the mixture is then dried under vacuum after rotary evaporation under reduced pressure to obtain curcumin phospholipid complex.

[0033]

[0034] Characterization of curcumin phospholipid complex 1. Combination Rate: Taking advantage of the fact that curcumin is insoluble in ether, while phospholipids and their complexes are readily soluble in ether, curcumin and phospholipids are combined under certain conditions. The reaction solvent is removed under reduced pressure, and the residue is dissolved in an appropriate amount of ether. After centrifugation, the supernatant is collected and dried under reduced pressure to obtain the curcumin-phospholipid complex. The precipitate is collected, dried, and weighed. The difference between the initial amount of curcumin (Wt) and the amount of precipitate (Wf) represents the amount of curcumin combined with the phospholipid. The combination percentage is calculated using the following formula: Composite rate (%) = (Wt - Wf) / Wt × 100.

[0035] 2. Equilibrium Solubility: Equal amounts of the examples and comparative samples were dissolved in pure water to obtain supersaturated solutions. After sonication, the solutions were placed in a 37°C constant temperature shaking water bath and shaken. After shaking for 10 hours, undissolved matter was observed, and shaking was continued overnight. The next day, the solutions were centrifuged (10000 rpm, 10 min), and the supernatant was diluted with an appropriate amount of methanol. After filtering through a 0.22 μm filter membrane, the OD value was measured by ultraviolet spectroscopy, and the solubility was calculated.

[0036] 3. Fourier Transform Infrared Analysis The potassium bromide (KBr) tableting method was used to prepare physical mixtures of curcumin, krill phospholipids, the curcumin phospholipid complex obtained in Example 1, and the curcumin phospholipid mixture obtained in Comparative Example 4 at 400-4000 cm⁻¹. -1 Infrared scanning was performed within the range, and the infrared spectrum is as follows: Figure 1 As shown.

[0037] The curcumin phospholipid complex obtained in Example 1 (line d) has a curcumin characteristic peak at 3503 cm⁻¹. -1 (-OH) disappears, P=O 1236.79cm -1 Towards 1234.65cm -1 Displacement, PO 1065.76cm -1 Towards 1060.39cm -1 The shift indicates that P=O reacted with PO; this suggests that the -OH group of curcumin may have associated with hydrogen bonds or intermolecular forces between the polar ends of phospholipids. However, the comparative sample 4 (line c), after simple physical mixing, did not show the aforementioned characteristic peak shift change, indicating that it did not undergo a reaction.

[0038] 4. X-ray diffraction (XRD) X-ray diffraction (XRD) was used to measure the curcumin, krill phospholipids, the phospholipid complex obtained in Example 1, and the physical mixture of curcumin and phospholipids obtained in Comparative Example 4. The voltage and current were 40 kV and 30 mA, respectively, the scanning speed was 4 (°) / min, and the scanning range was 5°~60°. The XRD patterns are shown below. Figure 2 As shown.

[0039] Curcumin monomers have sharp peaks and are small molecules with polycrystalline properties, while krill phospholipids exhibit amorphous properties. The physical mixture consists of the superposition of the crystal diffraction peaks of curcumin and the amorphous characteristic peaks of krill phospholipids. This result indicates that when curcumin and krill phospholipids are physically mixed, there is no direct interaction between the two, and curcumin still exists in the physical mixture in crystalline form.

[0040] In the curcumin phospholipid complex, the crystal diffraction peaks of curcumin completely disappeared, and it exhibited amorphous characteristics extremely similar to those of krill phospholipids. This means that curcumin transformed from a polycrystalline form to an amorphous form or was dispersed in a molecular state within the curcumin phospholipid complex, preventing its crystalline properties from being displayed. This indicates that the curcumin phospholipid complex was successfully prepared.

[0041] 5. Dispersibility: Weigh an appropriate amount of sample into pure water to prepare a 1 mg / mL solution; sonicate at 50℃ for 15 min to fully dissolve it, and characterize its particle size and polydispersity index (PdI) using a Malvern particle size analyzer.

[0042]

[0043] The data analysis in the table above shows that: 1. Comparison of Examples 1-3 shows that the curcumin phospholipid complex obtained when anhydrous ethanol is used as the organic solvent has the best composite rate, water solubility, and dispersion performance. 2. Comparison of Examples 1 and 4-8 shows that when the molar ratio of curcumin to phospholipid is 1:3, the curcumin-phospholipid complex has the best composite rate, water solubility, and dispersion performance. 3. Comparison of Examples 1 and 9-13 shows that the curcumin phospholipid complex obtained with a reactant concentration of 10 mg / ml exhibits the best composite rate, water solubility, and dispersion performance. 4. Comparison of Examples 1 and 14-17 shows that the curcumin phospholipid complex obtained at a reaction temperature of 50℃ has the best composite rate, water solubility, and dispersion performance. 5. Comparison of Examples 1 and 18-20 shows that the curcumin phospholipid complex obtained with phosphatidylcholine in krill phospholipids of 95 wt% exhibits the best composite rate, water solubility, and dispersion performance. 6. Compared with Comparative Example 1, Example 4 and Comparative Example 2 show that when the molar ratio of curcumin and phospholipid is too large or too small, it is not conducive to the product's compounding, water solubility, particle size, and dispersibility. 7. As can be seen from Example 1 compared with Comparative Example 3, the use of krill phospholipids is more beneficial to the product's compounding rate, water solubility, and dispersion performance. 8. As can be seen from Example 1 compared with Comparative Example 4, simply physically mixing curcumin and phospholipids will result in a significant decrease in the water solubility and dispersibility of the product.

[0044] Several oral formulation samples are provided below, wherein the curcumin phospholipid complex is selected from the sample prepared in Example 1 above.

[0045] Tablet 1 This embodiment provides a sample of curcumin phospholipid complex oral tablets: by mass, take 75 parts of the curcumin phospholipid complex sample from Example 1, 1 part of magnesium stearate, 4 parts of croscarmellose sodium cellulose, and 20 parts of microcrystalline cellulose; mix the above raw materials evenly, pass the granules through a 20-mesh sieve, dry them, and then compress them into tablets to obtain the curcumin phospholipid complex oral tablets.

[0046] Tablet 2 Based on the mass fractions, take 55 parts of the curcumin phospholipid complex sample from Example 1, 0.5 parts of talc, 5 parts of sodium carboxymethyl starch, and 30 parts of dicalcium phosphate; mix the above raw materials evenly, pass the granules through a 20-mesh sieve, dry them, and then compress them into tablets to obtain oral tablets of curcumin phospholipid complex.

[0047] Tablet 3 Based on the mass fractions, take 65 parts of the curcumin phospholipid complex sample from Example 1, 1.5 parts of talc, 3 parts of crospovidone, and 30 parts of microcrystalline cellulose; mix the above raw materials evenly, pass the granules through a 20-mesh sieve, dry them, and then compress them into tablets to obtain the curcumin phospholipid complex oral tablets.

[0048] Tablet 4 Based on the mass fractions, take 60 parts of the curcumin phospholipid complex sample from Example 1, 3 parts of silicon dioxide, 0.5 parts of crospovidone, and 45 parts of lactose; mix the above raw materials evenly, pass the granules through a 20-mesh sieve, dry them, and then compress them into tablets to obtain the curcumin phospholipid complex oral tablets.

[0049] Tablet 5 Based on the mass fractions, take 55 parts of the curcumin phospholipid complex sample from Example 1, 1 part of silicon dioxide, 4 parts of sodium carboxymethyl starch, and 45 parts of calcium hydrogen phosphate; mix the above raw materials evenly, pass the granules through a 20-mesh sieve, dry them, and then compress them into tablets to obtain oral tablets of curcumin phospholipid complex.

[0050] Comparison Tablet 1 The curcumin phospholipid complex sample in tablet 1 was replaced with the curcumin phospholipid complex sample in comparative example 3, that is, replaced with phospholipids derived from soybeans, while other components and proportions remained unchanged.

[0051] Comparison Tablet 2 The curcumin phospholipid complex sample in tablet 1 was replaced with the curcumin phospholipid physical mixture sample of Comparative Example 4, while other components and proportions remained unchanged.

[0052] Comparison Tablet 3 The curcumin phospholipid complex sample in tablet 1 was replaced with curcumin raw material, while other components and proportions remained unchanged.

[0053] Comparison Tablet 4 Without adding excipients, the curcumin phospholipid composition of Example 1 was simply compressed into tablets.

[0054] [Characteristics of tablets] 1. In vitro dissolution test The in vitro dissolution rate of the samples in the dissolution medium (PBS containing 0.5% SDS and pH 6.8) was determined using the paddle method. The paddle speed was 100 rpm and the water bath temperature was 37 ℃.

[0055] Samples of tablets 1-5 and control tablets 1-4 with the same turmeric quality were placed in a dissolution tank. 2 mL samples were taken at 5, 10, 15, 20, 30, 45, 60, 90, and 120 min respectively (with simultaneous replenishment of an equal volume of fresh dissolution medium at the same temperature). The samples were filtered through a 0.45 μm microporous membrane, and the absorbance of the filtrate was measured at 420 nm in the dark. Figure 3 As shown.

[0056] As can be seen from the dissolution curves, the dissolution rate of control tablet 3 was the worst, indicating poor dissolution due to the use of curcumin monomer technical material in tablet compression. Replacing the curcumin monomer technical material with a physical mixture of curcumin and krill phospholipids (control tablet 2) slightly improved the dissolution rate, but it was still lower than that of control tablet 4, which contained a curcumin phospholipid complex without other excipients. Under the same tablet formulation, krill phospholipid complex tablet 1 showed the best dissolution rate, with nearly 100% dissolution at 20 minutes, significantly better than control tablet 1 containing soybean phospholipid complex.

[0057] 2. Bioavailability Animal experiments: Thirty healthy male SD rats (weighing 180-200 g) were randomly divided into 5 groups. They were fasted for 12 h before administration but had free access to water. They were given 200 mg / kg (based on curcumin) by gavage and an aqueous solution of the sample. Blank blood was collected before administration. After administration, 0.3 mL of blood was collected from the retro-orbital venous plexus of the rats at 0.25, 0.5, 1, 2, 4, 6, 8, and 24 h. The blood samples were placed in centrifuge tubes containing heparin sodium and centrifuged at 3000 rpm for 10 min at 4 °C. The plasma was separated and stored at -80 °C. The plasma was analyzed by LC MS / MS.

[0058] Plasma sample processing: Take 20 μL of plasma, dissolve it in 80 μL of acetonitrile solution, shake for 2 min, centrifuge at 13000 rpm for 10 min at 4℃, take 80 μL of supernatant, add another 80 μL of acetonitrile, shake, centrifuge, take 100 μL of supernatant, dry it under nitrogen at 30℃ for 5-10 min, and then reconstitute the sample with 50 μL of methanol solution; finally, transfer it to a vial and place it in a -80℃ freezer for testing.

[0059] Liquid chromatography-mass spectrometry (LC-MS) conditions: Mobile phase: A: 900 mL water (containing 0.1% formic acid) + 900 μL formic acid B: Acetonitrile (containing 0.1% formic acid) 900 mL acetonitrile + 900 μL formic acid Elution gradient:

[0060] Conditions: C18 (4.6 mm × 250 mm, 5 μm) column Flow rate: 0.3 mL / min; detection mode: positive ion; ion pair used for quantitative analysis: m / z 369→177.

[0061] Results analysis: Blood drug concentrations were measured at different time points, and bioavailability was calculated. The results are as follows:

[0062] The table shows that the preparation of the oral formulation of curcumin phospholipid complex improved the bioavailability of curcumin. In 30 male SD rats, after a single oral dose of 200 mg / kg (calculated as curcumin) of aqueous solution from control tablets 3 and 1, the plasma Cg of curcumin was... max The concentrations were 12.33 ng / mL and 106.04 ng / mL, respectively. max The times were 129 min and 41 min, respectively; the AUC was calculated using the trapezoidal method. 0-tThe values ​​were 181.42 and 1498.82 ng / mL·h, respectively. From the data, the C of tablet 1 can be obtained. max and AUC 0-t These figures are 8.60 times and 8.26 times higher than those of the control tablet 3, respectively.

[0063] Comparing tablet 1 with tablet 1, it can be seen that using krill phospholipids can further improve the bioavailability of curcumin compared to using soybean phospholipids; comparing tablet 2 with tablet 1, it can be seen that the bioavailability of the product obtained by physical mixing alone will be significantly reduced; comparing tablet 4 with tablet 1, it can be seen that the selection of excipients can improve the bioavailability of curcumin.

[0064] The various embodiments in this specification are described in a progressive manner. Similar or identical parts between embodiments can be referred to interchangeably. Each embodiment focuses on describing the differences from other embodiments. In particular, the system embodiments are basically similar to the method embodiments, so the description is relatively simple; relevant parts can be referred to the descriptions in the method embodiments.

[0065] The above description is merely an embodiment of this application and is not intended to limit this application. Various modifications and variations can be made to this application by those skilled in the art. Any modifications, equivalent substitutions, improvements, etc., made within the spirit and principle of this application should be included within the scope of the claims of this application.

Claims

1. A curcumin phospholipid complex, characterized in that: It includes curcumin and marine phospholipids, wherein the molar ratio of curcumin to marine phospholipids is (1-5):(1-10).

2. The curcumin phospholipid complex according to claim 1, characterized in that: The molar ratio of curcumin to marine phospholipids is 1:(2-6).

3. The curcumin phospholipid complex according to claim 1, characterized in that: The marine phospholipid is krill phospholipid, and the phospholipid content in the krill phospholipid is not less than 50 wt%.

4. The curcumin phospholipid complex according to claim 3, characterized in that: The phosphatidylcholine content in the krill phospholipid is not less than 50 wt%; preferably, the phosphatidylcholine content in the krill phospholipid is not less than 70 wt%; preferably, the phosphatidylcholine content in the krill phospholipid is not less than 80 wt%.

5. The curcumin phospholipid complex according to claim 4, characterized in that: The phosphatidylcholine content in the krill phospholipids is not less than 95 wt%.

6. A method for preparing a curcumin phospholipid complex, characterized in that, The preparation is carried out according to the following steps: Curcumin and marine phospholipids are placed in an organic solvent, the molar ratio of curcumin to marine phospholipids is (1-5):(1-10), the mass concentration of the reactants is 2-20 mg / ml, and after magnetic stirring at 30-70℃ for 1-3 h, rotary evaporation is carried out. Unreacted curcumin is removed by adding diethyl ether, and after vacuum drying under reduced pressure for 8-14 h, the curcumin phospholipid complex is obtained.

7. The preparation method according to claim 6, characterized in that: The organic solvent is one or more of tetrahydrofuran, ethyl acetate, and anhydrous ethanol; preferably, the organic solvent is anhydrous ethanol; the reaction temperature is 50°C; the mass concentration of the reactant is 10 mg / ml; and the reaction time is 3 h.

8. An oral formulation of curcumin phospholipid complex, characterized in that: Includes the curcumin phospholipid complex according to any one of claims 1-5 or the curcumin phospholipid complex prepared according to any one of claims 6-7.

9. The oral formulation of curcumin phospholipid complex according to claim 8, characterized in that: By weight, the components include: 55-75 parts curcumin phospholipid complex, 0.5-3 parts lubricant, 0.5-5 parts disintegrant, and 20-45 parts excipient.

10. An oral formulation of curcumin phospholipid complex according to claim 9, characterized in that: The excipient is one or more of microcrystalline cellulose, dicalcium phosphate, and lactose; the lubricant is one or more of magnesium stearate, talc, and silica; and the disintegrant is one or more of croscarmellose sodium, carboxymethyl starch sodium, and croscarmellose.

Images